Revisiting IDO and its value as a predictive marker for anti-PD-1 resistance
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1479-5876
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Revisiting IDO and its value as a predictive marker for anti-PD-1 resistance ; volume:17 ; number:1 ; day:18 ; month:1 ; year:2019 ; pages:1-2 ; date:12.2019
Journal of translational medicine ; 17, Heft 1 (18.1.2019), 1-2, 12.2019
- Urheber
-
Moon, Peter Kim
Tran, Stephanie
Minhas, Paras Singh
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12967-019-1784-8
- URN
-
urn:nbn:de:101:1-2019022022122164711254
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:00 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Moon, Peter Kim
- Tran, Stephanie
- Minhas, Paras Singh
- SpringerLink (Online service)
Ähnliche Objekte (12)
Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study
The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells
Management of Localized Melanoma in the Anti-PD-1 Era
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
Changes in peripheral blood PD-1 receptor expression under anti-PD-1 Immune Checkpoint Therapy
Idő kérdése
Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study
The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells
Management of Localized Melanoma in the Anti-PD-1 Era
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
Changes in peripheral blood PD-1 receptor expression under anti-PD-1 Immune Checkpoint Therapy
Idő kérdése
Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study
The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells
Management of Localized Melanoma in the Anti-PD-1 Era
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
Changes in peripheral blood PD-1 receptor expression under anti-PD-1 Immune Checkpoint Therapy